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ABSTRACT
CT screening for lung cancer reduces mortality, but will cost Medicare ~2 billion 
dollars due in part to high false positive rates. Molecular biomarkers could augment 
current risk stratification used to select smokers for screening. Gene methylation in 
sputum reflects lung field cancerization that remains in lung cancer patients post-
resection. This population was used in conjunction with cancer-free smokers to 
evaluate classification accuracy of a validated eight-gene methylation panel in sputum 
for cancer risk. Sputum from resected lung cancer patients (n=487) and smokers 
from Lovelace (n=1380) and PLuSS (n=718) cohorts was studied for methylation of 
an 8-gene panel. Area under a receiver operating characteristic curve was calculated 
to assess the prediction performance in logistic regressions with different sets of 
variables. The prevalence for methylation of all genes was significantly increased in 
the ECOG-ACRIN patients compared to cancer-free smokers as evident by elevated 
odds ratios that ranged from 1.6 to 8.9. The gene methylation panel showed lung 
cancer prediction accuracy of 82–86% and with addition of clinical variables improved 
to 87–90%. With sensitivity at 95%, specificity increased from 25% to 54% comparing 
clinical variables alone to their inclusion with methylation. The addition of methylation 
biomarkers to clinical variables would reduce false positive screens by ruling out one-
third of smokers eligible for CT screening and could increase cancer detection rates 
through expanding risk assessment criteria.
INTRODUCTION
Lung cancer (LC) remains the leading cause of 
cancer-related death for men and women in the US 
[1]. The success of CT screening in the National Lung 
Screening trial (NLST) for reducing LC mortality led to 
the recommendation by The Centers for Medicare and 
Medicaid (CMS) to screen people ages 55 to 77 who have 
a minimum 30 pack-year smoking history and currently 
smoke or have quit within the past 15 years [2]. However, 
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these eligibility criteria or similar criteria by NCCN only 
capture 40% of the incident LC cases [3, 4]. Screening 
is estimated to save more than 12,000 lives, but cost 
Medicare ~2 billion dollars, annually [5, 6]. This is due 
in part to the high false positive rate of CT screening as 
evident by the 39% of NLST participants that had at least 
one positive screening result (detection of indeterminate 
nodule) with >96% of those findings being classified as 
false positive [7].
The addition of molecular biomarkers interrogated 
in accessible biologic fluids such as sputum could provide 
better risk stratification to prioritize selection of smokers 
for CT screening and thereby substantially improve its 
predictive value and lower costs by reducing follow-
up screens and biopsies [8, 9]. Gene silencing through 
methylation of cytosine in CpG islands in conjunction 
with chromatin remodeling leads to the development 
of heterochromatin of the gene promoter region, 
which denies access to regulatory proteins needed for 
transcription [10]. This epigenetically driven process 
is a major and causal event silencing hundreds of genes 
involved in all aspects of normal cellular function during 
LC initiation and progression [10]. Others and we have 
shown that gene specific promoter hypermethylation 
detected in sputum provides an assessment of field 
cancerization within the lungs of smokers that in turn 
predicts LC [11–17]. Specifically, our group showed 
that detecting gene methylation in exfoliated cells could 
predict cancer up to 18 months prior to clinical diagnosis, 
and was independently validated through case-control 
studies for predicting LC risk [11, 12]. However, the 
incorporation of this validated methylation panel in 
sputum into existing risk assessment models has not 
been assessed in a population-based setting that could 
identify high-risk smokers who would benefit most 
from a CT screen. A major challenge in conducting a 
prospective study for predicting LC risk is the need for 
a large population of high-risk smokers to yield enough 
cases of LC to accurately define the performance of the 
methylation panel.
Our previous case-control study used prevalent 
Stage I LC patients compared to cancer-free smoker 
controls to validate gene methylation panels for predicting 
LC [12]. Prior findings support our hypothesis of an 
expanding field of precancerous changes throughout 
the aerodigestive tract demonstrated initially through 
histologic changes and subsequently by increasing 
frequencies of genetic and epigenetic changes detected in 
exfoliated cells as the cancer develops [11, 16, 18]. Thus, 
the increase in number of cancer-associated methylated 
genes, rather than a single gene, is used in risk prediction 
[12]. The current study addressed whether our validated 
gene methylation panel could be extended to improve the 
existing risk prediction model used to recommend people 
for a CT screen. To accomplish this goal we used three 
cohorts of people: ECOG-ACRIN5597 trial participants 
who had a confirmed Stage I diagnosis of LC (based on 
pathology following surgical resection), the Lovelace 
Smokers Cohort ([LSC], current and former smokers at 
high risk for LC), and the PLuSS Smokers cohort (also 
current and former smokers at high risk for LC). The 
ECOG-ACRIN5597 participants were recruited from 
within the U.S. and Canada to participate in a prevention 
trial using L-selenomethione [19]. Patients had undergone 
surgical resection prior to trial enrollment and baseline 
sputum was obtained prior to randomization to the placebo 
or intervention group. Gene methylation in sputum reflects 
lung field cancerization that remains in lung cancer 
patients post-resection [20]. We hypothesized that because 
our gene methylation test is based on detecting the field of 
injury in the lung and not the actual small tumor present, 
the ECOG-ACRIN5597 trial participants would still have 
extensive field cancerization and serve in our study as 
people who should receive a CT screen, while the smokers 
selected were all cancer-free at time of sputum collection. 
We initially evaluated the utility of the eight gene panel 
to classify risk for LC by comparing gene methylation 
prevalence at baseline in the ECOG-ACRIN5597 patients 
who met the Medicare guidelines to receive a CT screen 
to screen eligible subjects from two cancer-free smoker 
cohorts (LSC and PLuSS) described previously [21]. In 
addition, the performance of our methylation panel was 
assessed in all ECOG-ACRIN5597 patients who provided 
baseline sputum compared to LSC or PLuSS current or 
former smokers irrespective of meeting eligibility for 
receiving a CT screen.
RESULTS
Study population
The characteristics of the entire study populations 
are shown in Table 1 . As expected the ECOG-ACRIN 
LC cases were slightly older and more had quit smoking. 
Pack years were available for 259 LC cases and were 
comparable to current and former smokers in the PLuSS 
cohort, but significantly greater than the LSC cohort.
Gene methylation in sputum as a classifier 
for lung cancer risk in CT screen eligible 
smokers
The utility of the eight gene panel to classify risk 
for LC was evaluated by comparing gene methylation 
prevalence at baseline in the 371 ECOG-ACRIN5597 
patients who met the Medicare guidelines to receive a 
CT screen to screen eligible subjects from two cancer-
free smoker cohorts (LSC [n = 466] and PLuSS [n =597]) 
described previously [21].Comparative characteristics of 
“screen eligible” subjects are detailed in Table 2. Two 
analyses were performed to evaluate prediction accuracy 
for LC by comparing ECOG-ACRIN5597 and LSC versus 
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ECOG-ACRIN5597 and PLuSS cohort. The prevalence 
for methylation of all genes was significantly increased 
in the ECOG-ACRIN patients compared to cancer-free 
smokers as evident by elevated odds ratios that ranged 
from 1.6 to 8.9 (Table 3). ROC curves comparing the 
eight-gene methylation panel for ECOG-ACRIN5597 to 
LSC or PLuSS showed classification accuracy of 82% 
and 86% (Figure 1A, 1B). ROC curves restricted to the 
subset of ECOG-ACRIN5597 subjects (n = 194) with 
pack years available were identical to those in Figure 1 
(classification accuracies of 89% and 91%, respectively). 
Most important, the gene panel when added to the clinical 
variables increased the prediction accuracy from 76% to 
87% (p = 7.2 × 10-9 for delta area under the curve [AUC]) 
and 74% to 90% (p =3.2 × 10-16 for delta AUC) when 
ECOG-ACRIN5597 subjects were compared to LSC or 
PLuSS, respectively (Figure 1, Table 4 ).
Random sampling to match for the difference in 
distributions of age, sex, and smoking status between 
ECOG-ACRIN5597 and LSC/PLuSS had no effect 
on prediction accuracy of the gene panel (Table 4, 
Supplementary Figure 1). With the sensitivity set 
at 95%, the addition of the methylation biomarkers 
increased specificity from 25% (clinical variables only) 
to 54%, while NPV and PPV were increased from 88% 
to 94% and 47% to 58%, respectively (average values 
comparing ECOG-ACRIN5597 versus LSC/PLuSS; 
Table 4).
Table 1: Characteristics of study populations
Variable ECOG-ACRIN LSC PLuSS P value
N 487 1380 718
Age (mean ± SD) 66.4 ± 8.8 57.0 ± 9.6 64.6 ± 5.1 <0.00012
Sex (male, %) 268 (55) 339 (25) 234 (33) <0.0001
Smoking status
 Current 160 (33) 756 (55) 424 (59) <0.0001
 Former 327 (67) 624 (45) 294 (41)
Pack-years1 (mean ±SD) 56 ± 37 41 ± 20 55 ± 21 <0.00012
1Pack-years were available for 259 of the ECOG-ACRIN patients.
2Comparing ECOG-ACRIN to LSC. P values are calculated using χ2 for binary or categorical variables and one-way 
ANOVA for continuous variables.
Figure 1: ROC curves for comparing the sensitivity and specificity for the eight-gene methylation panel with and 
without clinical risk factors between ECOG-ACRIN and LSC (A) or PLuSS (B) for classifying lung cancer risk.
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Gene methylation classifier extends lung cancer 
risk assessment beyond medicare screening 
guidelines
The performance of the gene methylation panel 
was also evaluated in the ECOG-ACRIN versus LSC 
or PLuSS cohorts independent of their age, smoking 
history and smoking status (years quit), albeit everyone 
was 40 years and older and had smoked a minimum of 
10 pack years. This design increased the samples sizes 
to 487, 1380, and 718 for the ECOG-ACRIN, LSC, and 
PLuSS cohorts, respectively. ROC curves comparing the 
eight-gene methylation panel for ECOG-ACRIN5597 to 
LSC or PLuSS each showed classification accuracy of 
88% when combining clinical risk factors with the 8-gene 
methylation panel. Accordingly, this relaxed inclusion 
criteria also did not significantly diminish specificity when 
sensitivity was set at 95%.
DISCUSSION
This large cross sectional study of smokers 
provides compelling support that a significant increase in 
classification accuracy and accompanied specificity for 
predicting LC risk can be achieved by addition of a gene 
methylation panel in sputum to the inclusion variables for 
CT screening when comparing these cancer patients to 
two geographically distinct cancer-free smoker cohorts. 
Moreover, classification accuracy of the methylation 
panel was similar when relaxing the Medicare inclusion 
criteria for CT to include all ECOG-ACRIN cases 
that smoked compared to all cancer-free subjects from 
LSC and PLuSS. A limitation of these studies was that 
our assessment was restricted to the ~70% of smokers 
who produce sputum. However, with the advent of the 
Lung Flute, most individuals that do not spontaneously 
produce sputum will be able to provide a specimen for 
risk assessment [22]. Thus, implementation of this gene 
methylation panel for population-based screening could 
be a paradigm shift for LC management by providing a 
much improved risk assessment model that will save more 
lives through increased number of screen-detected cancer, 
while greatly reducing the number of false screens through 
exclusion of lower risk smokers.
The retrospective nature of this study design 
allowed us to define the classification accuracy of the 
biomarker panel in a sample size of cases (n = 487) that 
was comparable to that detected by the NLST screening 
trial of 53,439 smokers [7]. Importantly, using participants 
from the ECOG-ACRIN5597 trial also addressed for 
the first time the generalizability of a gene methylation 
biomarker panel for risk assessment through studying LC 
cases from across the U.S. and Canada with comparison 
to two geographically distinct cohorts of smokers. 
Another major distinguishing feature of our study beyond 
sample size from other sputum-based risk assessment 
publications is the continued reproducibility regarding the 
performance of genes within this biomarker panel across 
five independent studies [11, 12, 23–25]. This outcome 
likely results from the fact that the genes studied are not 
methylated in normal cells of any lineage thereby being 
cancer-specific and the use of the nested, MSP assay 
that has a reproducible sensitivity of 1 methylated allele 
in 20,000 unmethylated alleles to allow interrogation 
of sputum, a heterogeneous mixture of cells where the 
epithelial fraction is often less than 3% [11]. Moreover, 
high specificity is maintained in the stage 2 PCR for 
detecting methylated alleles through the use of annealing 
temperatures that exceed the melting point of the primers 
and short denaturation and extension cycles (15–20 sec; 
[11]). Finally, the fact that high classification accuracy was 
achieved through comparison of sputum from resected LC 
cases to controls strongly substantiates that the expanding 
field of injury with concomitant methylation is the major 
feature distinguishing cases from controls.
While our studies with a validated gene methylation 
panel in sputum have improved classification accuracy for 
LC in screen-eligible smokers as evident by an increase in 
Table 2: Comparative demographics between ECOG-ACRIN, LSC, and PLuSS cohort members eligible for CT 
screening
Variable ECOG-ACRIN LSC PLuSS P value
N 371 466 597
Age (mean ± SD) 67 ± 5.9 63.5 ± 5.7 64.4 ± 4.5 <0.0001
Sex (male, %) 210 (57) 119 (26) 210 (35) <0.0001
Smoking status <0.0001
 Current 119 (32) 277 (59) 390 (65)
 Former 252 (68) 189 (41) 207 (35)
Pack-years1 (mean ±SD) 67 ± 30 56 ± 24 59 ± 19
1Pack-years were available for 194 of the ECOG-ACRIN patients.
P values are calculated using χ2 for binary or categorical variables and one-way ANOVA for continuous variables.
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specificity from 24% to 56% with sensitivity set at 95%, 
adding other methylated genes to our panel is unlikely 
to yield significant improvement due to the correlation 
among genes for differentiating case status [12]. Rather, 
independent sets of biomarkers that can be used in 
conjunction with this gene methylation panel are needed 
to significantly extend specificity. Changes in circulating 
metabolites that can be quantitated are emerging as 
sensitive readouts for many diseases and a plasma 
metabolome signature, because of its dimensionality 
resulting from genetic and epigenetic changes driving 
the expansion of field cancerization in the smoker’s lung, 
could extend our prediction model beyond methylation 
biomarkers [26–31]. While this approach remains 
untested, promising recent metabolomic profiling studies 
of moderate sample size are identifying discriminatory 
metabolites with LC classification accuracy of 77–88% 
[32, 33].
The ultimate translation of this work should be to 
provide primary care and/or pulmonary physicians with 
the option of ordering a low cost (≤ $200) insurance 
reimbursable validated LC risk assessment test to guide 
decision making regarding receiving a CT scan. Our 
model to date significantly improves classification 
accuracy beyond the current Medicare guideline, will 
allow expanding the number of smokers considered for 
screening, and should better define eligibility for receiving 
a CT scan by removing smokers with a low probability 
for LC based on the addition of methylation to the risk 
assessment. Our patented technology [34] is amenable 
to a CLIA setting through development of robotic/liquid 
handling for sputum processing, DNA isolation, bisulfite 
modification, and assembling of the Stage I and II MSP 
reactions in a 96-well format in conjunction with low 
cost SYBR-Green based detection of methylated products 
using real-time PCR.
Table 3: Comparison of gene promoter methylation prevalence in sputum from ECOG-ACRIN lung cancer patients 
to the lovelace smokers cohort (LSC) and pittsburgh PLuSS cohort
Gene ECOG-ACRIN 
(n=371)1
LSC (n=466)1 PLuSS (n=597)1 OR2 (95% CI) 
(ECOG/LSC)
OR2 (95% CI) 
(ECOG/PLuSS)
P16 132 (36) 92 (20) 89 (15) 2.3 (1.6 – 3.2) 3.2 (2.3 – 4.5)
MGMT 152 (42) 125 (26) 140 (23) 2.0 (1.5 – 2.8) 2.4 (1.8 – 3.2)
DAPK 157 (43) 87 (19) 77 (13) 3.3 (2.3 – 4.6) 5.0 (3.6 – 7.1)
RASSF1A 37 (10) 2 (0.4) 0 7.4 (1.8 – 31.4) NC
GATA4 265 (73) 174 (37) 198 (33) 3.9 (2.8 – 5.3) 4.9 (3.6 – 6.6)
GATA5 164 (45) 62 (13) 55 (9) 5.3 (3.6 – 7.6) 7.9 (5.5 – 11.5)
PAX5ɑ 116 (32) 87 (19) 68 (11) 1.6 (1.2 – 2.3) 3.2 (2.2 – 4.5)
PAX5β 117 (32) 33 (7) 30 (5) 6.2 (4.0 – 9.8) 8.9 (4.7 – 14.1)
NC, not able to calculate. 1 Number in parenthesis under columns of ECOG-ACRIN, LSC, and PLuSS is prevalence of gene 
methylation. 2Adjustment for age, sex, and smoking status was included in logistic regression. Cohort identifier was coded 
as two dummy variables with ECOG-ACRIN set as the reference.
Table 4: Performance of gene methylation as a classifier for lung cancer risk
AUC (95% CI) P value1 Sensitivity2 Specificity PPV (%) NPV (%)
ECOG-ACRIN vs. LSC
 Clinical risk factors 0.76 (0.73–0.79) 95 29 51 88
 Methylation panel 0.82 (0.79–0.85) 0.0018 95 31 51 89
 Clinical + methylation 0.87 (0.85–0.90) 7.2 × 10-9 95 52 60 93
ECOG-ACRIN vs. PLuSS
 Clinical risk factors 0.74 (0.71–0.79) 95 24 44 89
 Methylation panel 0.86 (0.84–0.89) 1.2 × 10-9 95 47 52 94
 Clinical + methylation 0.90 (0.88–0.92) 3.2 × 10-16 95 56 56 94
1P value for delta AUC with model containing clinical risk factors only as the reference. 2Sensitivity set to 95%.
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METHODS
Subject recruitment and biospecimen collection
Study participants were resected LC patients from 
a prevention trial and subjects from two geographically 
distinct cancer free smoker cohorts. Eligibility criteria 
for participation in the prevention trial included the 
following: age ≥ 18 years; 6 to 36 months from complete 
resection of histologically proven stage IA (pT1N0) or 
stage IB (pT2N0) non-small cell LC (carcinoid tumors 
were excluded [19]). The institutional review board for 
human studies approved the protocols and written consent 
was obtained from subjects. Following consent onto the 
correlative study, the Lovelace study coordinator sent a 
collection kit to the study site. Sputum was collected at 
time of entry onto study. Sputum was collected from 85% 
of ECOG-ACRIN patients within 18 months post-surgery.
Each participant was asked to provide two 
consecutive spontaneous sputum samples collected at 
home at each time point as described previously [11]. 
Study participants placed the sputum cups in a postage-
paid mailer addressed to the study coordinator at Lovelace. 
Material from the second 3-day pooled sputum was used 
for this study. The collection of two sputum samples at 
each time point was based on the finding by Kennedy 
et al. [35] that the second sample has a higher success 
rate (80%) in producing an adequate sputum sample 
based on established cytologic standards, attributed to a 
‘learning effect’ in adequate sputum collection. Following 
receipt, the sputum samples were pelleted and washed in 
Saccomanno’s fixative. A small portion was smeared onto 
two or three slides and stained with Papanicoleau prior to 
cytologic diagnosis with the remaining sample stored at 
-80°C until time for DNA isolation. Sputum containing 
epithelial cells from the upper or lower airways has proven 
satisfactory for methylation assays and using these criteria, 
virtually 100% of samples were adequate for study [11].
Two cancer-free cohorts, the LSC and Pittsburgh 
PLuSS Cohort (PLuSS), were used to validate the 
classification accuracy of the gene methylation panel 
for predicting LC risk [21, 36]. These participants were 
cancer-free and methylation was assessed in sputum 
collected at cohort enrollment.
DNA isolation and methylation specific PCR
Sputum DNA was isolated using methods 
previously described with yields of DNA that ranged 
from 5–100 μg [11, 12]. The eight genes selected were 
based on positive performance in our initial nested, case-
control study in a Colorado cohort [11]. These genes 
included P16, MGMT, DAPK, RASSF1A, GATA4, 
GATA5, PAX5α and PAX5β. These genes are cancer 
specific genes methylated solely in epithelial cells. DNA 
was bisulfite modified and two-stage, nested methylation 
specific polymerase chain reaction (MSP) assays were 
used for increased sensitivity for detection of promoter 
methylation in sputum and plasma as described [11]. 
Methylation was scored as positive or negative based on 
the detection of a visible band in the gel. The immense 
cellular heterogeneity in sputum, where the epithelial 
fraction is typically <3% of the specimen, limits the 
ability to quantitate methylation, thus methylation was 
scored as positive or negative.
Statistical analysis
The association between methylation of each gene 
measured in sputum collected at baseline and risk for 
LC using ever smokers enrolled in LSC (n=466), PLuSS 
(n=597), and ECOG-ACRIN5597 (n=371) was assessed 
using logistic regression. Study subjects were restricted 
to those who met the Medicare screening criteria with 
exception of pack years that was available for 194 of 
the 371 ECOG-ACRIN subjects [2]. Area under the 
curve (AUC) of a receiver operating characteristic 
(ROC) curve was calculated to assess the prediction 
performance of the logistic regressions with different 
sets of covariates. The basic model included age (as a 
continuous variable), sex, and smoking status (as a binary 
variable) that represent risk factors for LC available from 
all groups. Methylation status of each gene was defined 
as methylated or unmethylated based on the gel image 
with respect to detecting a methylated PCR product. 
The methylation status of the eight genes as eight 
independent variables was included in the basic model 
to evaluate the delta change in AUC. The methylation 
index approach showed prediction performance that 
was inferior to using the methylation status of each 
individual gene in the model (not shown). This may be 
due to the fact that individual gene methylation is low 
to moderately correlated between each other and their 
likely difference in magnitude with respect to driving 
lung cancer development does not support using equal 
weight as done with the methylation index. Estimates of 
sensitivity, specificity, negative and positive predictive 
value (NPV, PPV) were calculated. Analyses were 
expanded to assess AUC and ROC using all ECOG-
ACRIN subjects (n = 487) compared to LSC (n = 1380) 
or PLuSS (n = 718) who had provided baseline sputum 
for methylation interrogation, irrespective of meeting 
Medicare screening criteria. All statistical analyses used 
two-sided tests and were conducted using SAS 9.3 and 
R 3.1.
Abbreviations
LC: lung cancer, NLST: National Lung Screening 
trial, CMS: The Centers for Medicare and Medicaid, 
LSC: Lovelace Smokers Cohort, PLuSS: Pittsburgh 
PLuSS Cohort, AUC: area under the curve, ROC: receiver 
operator characteristic, NPV: negative predictive value, 
PPV: positive predictive value.
Oncotarget63984www.impactjournals.com/oncotarget
ACKNOWLEDGMENTS
This work was primarily supported by National Cancer 
Institute grant R01 CA095568 (SAB). The State of New 
Mexico as a direct appropriation from the Tobacco Settlement 
Fund to SAB through collaboration with University of 
New Mexico provided initial support to establish the LSC. 
R01CA097356 (SAB) and NIH/NCI P30 CA118100 
provided additional support. The PLuSS cohort was 
established and supported through the NCI SPORE in Lung 
Cancer grant P50 CA090440 to the University of Pittsburgh 
(J.M.S.). This study was also supported in part by the ECOG-
ACRIN Cancer Research Group (Robert L. Comis, MD and 
Mitchell D. Schnall, MD, PhD, Group Chairs Co-Chairs) 
by Public Health Service Grants CA180794, CA180820, 
CA180864, CA180844, CA180858, CA189828 and the 
National Cancer Institute, National Institutes of Health and 
the Department of Health and Human Services.
CONFLICTS OF INTEREST
The authors declare no competing financial 
interests.
REFERENCES
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA 
Cancer J Clin. 2014; 64:9-29.
2. Centers for Medicare & Medicaid Services. Decision memo 
for screening for lung cancer with low dose computed 
tomography (LDCT) (CAG-00439N). 2015.
3. Wood DE, Kazerooni E, Baum SL, Dransfield MT, Eapen 
GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, 
Kumar R, Lackner RP, Leard LE, Leung AN, et al. Lung 
cancer screening, version 1.2015: featured updates to the 
NCCN guidelines. J Natl Compr Canc Netw. 2015; 13:23-
34; quiz 34.
4. Yang P, Wang Y, Wampfler JA, Xie D, Stoddard SM, She J, 
Midthun DE. Trends in subpopulations at high risk for lung 
cancer. J Thorac Oncol. 2016; 11:194-202.
5. Roxanne Nelson. CT lung cancer screening would cost 
medicare $9 billion. Medscape. 2015.
6. Roth JA, Sullivan SD, Goulart BH, Ravelo A, Sanderson 
JC, Ramsey SD. Projected clinical, resource use, and fiscal 
impacts of implementing low-dose computed tomography 
lung cancer screening in medicare. J Oncol Pract. 2015; 
11:267-272.
7. National Lung Screening Trial Research Team, Aberle DR, 
Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom 
RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced 
lung-cancer mortality with low-dose computed tomographic 
screening. N Engl J Med. 2011; 365:395-409.
8. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, 
prognosis and treatment selection. Nat Rev Cancer. 2005; 
5:845-856.
9. Belinsky SA. Gene-promoter hypermethylation as a 
biomarker in lung cancer. Nat Rev Cancer. 2004; 4:707-717.
10. Belinsky SA. Unmasking the lung cancer epigenome. Annu 
Rev Physiol. 2015; 77:453-474.
11. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers 
J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, 
Franklin WA, Herman JG, Baylin SB, et al. Promoter 
hypermethylation of multiple genes in sputum precedes 
lung cancer incidence in a high-risk cohort. Cancer Res. 
2006; 66:3338-3344.
12. Leng S, Do K, Yingling CM, Picchi MA, Wolf HJ, Kennedy 
TC, Feser WJ, Baron AE, Franklin WA, Brock MV, Herman 
JG, Baylin SB, Byers T, et al. Defining a gene promoter 
methylation signature in sputum for lung cancer risk 
assessment. Clin Cancer Res. 2012; 18:3387-3395.
13. Konno S, Morishita Y, Fukasawa M, Shu Y, Wang D, 
Tanaka R, Minami Y, Iijima T, Noguchi M. Anthracotic 
index and DNA methylation status of sputum contents 
can be used for identifying the population at risk of lung 
carcinoma. Cancer. 2004; 102:348-354.
14. Olaussen KA, Soria JC, Park YW, Kim HJ, Kim SH, Ro 
JY, Andre F, Jang SJ. Assessing abnormal gene promoter 
methylation in paraffin-embedded sputum from patients 
with NSCLC. Eur J Cancer. 2005; 41:2112-2119.
15. Wang YC, Hsu HS, Chen TP, Chen JT. Molecular diagnostic 
markers for lung cancer in sputum and plasma. Ann N Y 
Acad Sci. 2006; 1075:179-184.
16. Hsu HS, Chen TP, Wen CK, Hung CH, Chen CY, 
Chen JT, Wang YC. Multiple genetic and epigenetic 
biomarkers for lung cancer detection in cytologically 
negative sputum and a nested case-control study for risk 
assessment. J Pathol. 2007; 213:412-419.
17. Hubers AJ, Brinkman P, Boksem RJ, Rhodius RJ, Witte 
BI, Zwinderman AH, Heideman DA, Duin S, Koning R, 
Steenbergen RD, Snijders PJ, Smit EF, Sterk PJ, Thunnissen 
E. Combined sputum hypermethylation and eNose analysis 
for lung cancer diagnosis. J Clin Pathol. 2014; 67:707-711.
18. Auerbach O, Hammond EC, Garfinkel L. Changes in 
bronchial epithelium in relation to cigarette smoking, 1955-
1960 vs. 1970-1977. N Engl J Med. 1979; 300:381-385.
19. Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, 
Belinsky SA, Johnson DH, Johnston MR, Goodman 
G, Clamon G, Okawara G, Marks R, Frechette E, et al. 
Randomized, double-blind, placebo-controlled, phase III 
chemoprevention trial of selenium supplementation in 
patients with resected stage I non-small-cell lung cancer: 
ECOG 5597. J Clin Oncol. 2013; 31:4179-4187.
20. Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, 
Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch 
FR, Heasley L, Bunn PA Jr, Franklin WA. Persistence of 
Oncotarget63985www.impactjournals.com/oncotarget
bronchial dysplasia is associated with development of 
invasive squamous cell carcinoma. Cancer Prev Res (Phila). 
2016; 9:96-104.
21. Leng S, Liu Y, Weissfeld JL, Thomas CL, Han Y, Picchi MA, 
Edlund CK, Willink RP, Gaither Davis AL, Do KC, Nukui 
T, Zhang X, Burki EA, et al. 15q12 variants, sputum gene 
promoter hypermethylation, and lung cancer risk: a GWAS 
in smokers. J Nat Cancer Inst. 2015; 107(5).
22. Anjuman N, Li N, Guarnera M, Stass SA, Jiang F. 
Evaluation of lung flute in sputum samples for molecular 
analysis of lung cancer. Clin Transl Med. 2013; 2:15.
23. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, 
Saccomanno G, Gabrielson E, Baylin SB, Herman JG. 
Aberrant methylation of p16(INK4a) is an early event in 
lung cancer and a potential biomarker for early diagnosis. 
Proc Nat Acad Sci U S A. 1998; 95:11891-11896.
24. Palmisano WA, Divine KK, Saccomanno G, Gilliland 
FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung 
cancer by detecting aberrant promoter methylation in 
sputum. Cancer Res. 2000; 60:5954-5958.
25. Hubers AJ, Heideman DA, Duin S, Witte BI, de Koning 
HJ, Groen HJ, Prinsen CF, Bolijn AS, Wouters M, van der 
Meer SE, Steenbergen RD, Snijders PJ, Uyterlinde A, et al. 
DNA hypermethylation analysis in sputum of asymptomatic 
subjects at risk for lung cancer participating in the NELSON 
trial: argument for maximum screening interval of 2 years. J 
Clin Pathol. 2017; 70:250-254.
26. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, 
Brakenhoff RH. A genetic explanation of Slaughter’s 
concept of field cancerization: evidence and clinical 
implications. Cancer Res. 2003; 63:1727-1730.
27. Licchesi JD, Westra WH, Hooker CM, Herman JG. 
Promoter hypermethylation of hallmark cancer genes in 
atypical adenomatous hyperplasia of the lung. Clin Cancer 
Res. 2008; 14:2570-2578.
28. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, 
Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, 
Smith TM, Moots PP, Lechner JF, Stidley CA, Crowell RE. 
Aberrant promoter methylation in bronchial epithelium 
and sputum from current and former smokers. Cancer Res. 
2002; 62:2370-2377.
29. Ooi AT, Gower AC, Zhang KX, Vick JL, Hong L, Nagao 
B, Wallace WD, Elashoff DA, Walser TC, Dubinett SM, 
Pellegrini M, Lenburg ME, Spira A, P Gomperts BN. 
Molecular profiling of premalignant lesions in lung squamous 
cell carcinomas identifies mechanisms involved in stepwise 
carcinogenesis. Cancer Prev Res (Phila). 2014; 7:487-495.
30. Jakubek Y, Lang W, Vattathil S, Garcia M, Xu L, Huang 
L, Yoo SY, Shen L, Lu W, Chow CW, Weber Z, Davies G, 
Huang J, et al. Genomic landscape established by allelic 
imbalance in the cancerization field of a normal appearing 
airway. Cancer Res. 2016; 76:3676-3683.
31. Nakachi I, Rice JL, Coldren CD, Edwards MG, Stearman 
RS, Glidewell SC, Varella-Garcia M, Franklin WA, Keith 
RL, Lewis MT, Gao B, Merrick DT, Miller YE, Geraci 
MW. Application of SNP microarrays to the genome-wide 
analysis of chromosomal instability in premalignant airway 
lesions. Cancer Prev Res (Phila). 2014; 7:255-265.
32. Puchades-Carrasco L, Jantus-Lewintre E, Perez-Rambla C, 
Garcia-Garcia F, Lucas R, Calabuig S, Blasco A, Dopazo J, 
Camps C, Pineda-Lucena A. Serum metabolomic profiling 
facilitates the non-invasive identification of metabolic 
biomarkers associated with the onset and progression of 
non-small cell lung cancer. Oncotarget. 2016; 7:12904-
12916. doi: 10.18632/oncotarget.7354.
33. Mazzone PJ, Wang XF, Beukemann M, Zhang Q, Seeley M, 
Mohney R, Holt T, Pappan KL. Metabolite profiles of the 
serum of patients with non-small cell carcinoma. J Thorac 
Oncol. 2016; 11:72-78.
34. Belinsky S. Gene methylation as a biomarker in sputum. 
US Patent 9 512 483. 2016.
35. Kennedy TC, Proudfoot SP, Piantadosi S, Wu L, 
Saccomanno G, Petty TL, Tockman MS. Efficacy of two 
sputum collection techniques in patients with air flow 
obstruction. Acta Cytol. 1999; 43:630-636.
36. Wilson DO, Weissfeld JL, Fuhrman CR, Fisher SN, Balogh 
P, Landreneau RJ, Luketich JD, Siegfried JM. The Pittsburgh 
Lung Screening Study (PLuSS): outcomes within 3 years of a 
first computed tomography scan. Am J Respir Crit Care Med. 
2008; 178:956-961.
